Reviva Pharmaceuticals Holdings, INC 8-K filings
OQB
8-K: Reviva Pharmaceuticals Secures European Patent for Brilaroxazine in Pulmonary Hypertension Treatment
Reviva Pharmaceuticals has been granted a European patent for the use of brilaroxazine in treating pulmonary hypertension, expanding its global patent portfolio.
OQB
Reviva Pharmaceuticals has entered into a definitive agreement for a $3 million registered direct offering of common stock and warrants.
OQB
Reviva Pharmaceuticals announced an enrollment update for its open-label extension study of brilaroxazine in schizophrenia, with 358 patients enrolled and topline data expected in Q4 2024.
OQB
8-K: Reviva Pharmaceuticals Reports Q1 2024 Results and Outlines Brilaroxazine Clinical Trial Progress
Reviva Pharmaceuticals announced its first quarter 2024 financial results and provided updates on the clinical development of brilaroxazine, including alignment with the FDA on its Phase 3 program for schizophrenia.
OQB
8-K: Reviva Pharmaceuticals Gains FDA Alignment on Phase 3 Program for Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals has secured FDA agreement on its Phase 3 clinical trial program for brilaroxazine in schizophrenia, potentially paving the way for a New Drug Application (NDA).
OQB
Reviva Pharmaceuticals announced its full year 2023 financial results, highlighted positive clinical trial data for its lead drug candidate, and outlined key milestones for the coming year.
OQB
Reviva Pharmaceuticals announced it will restate its financial statements for fiscal year 2022 and interim periods in 2022 and 2023 due to errors in recognizing research and development expenses.